glp-1 agonists gastrointestinal side effects constipation diarrhea Clinical Recommendations to Manage Adverse Events in Patients Treated with Receptor Agonists: A Multidisciplinary Expert Consensus Exploring the Side Effects of
Description
this activates the tubulo-glomerular feedback responsible for afferent arteriole dilation and efferent arteriole constriction and, ultimately, leads to glomerular hyperfiltration and hypertension
Small molecule therapies include upadacitinib (Rinvoq), a JAK inhibitor that blocks intracellular signaling pathways involved in inflammation
Weight management with GLP-1 medications often requires ongoing treatment
Lillys Taltz (Ixekizumab) and Zepbound (Tirzepatide) Used Together Delivered Superior Efficacy in First-of-Its-Kind Phase 3B Trial for Adults With Active Psoriatic Arthritis and Obesity or Overweight
May 15, 2024
Clinical evidence supporting the anti-inflammatory effects of GLP-1 receptor agonists comes primarily from cardiovascular outcome trials and mechanistic studies, though most research has examined standard therapeutic doses rather than specifically low-dose regimens
